Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
24,370,010
-
Share change
-
-215,017
-
Total reported value
-
$396,509,258
-
Put/Call ratio
-
67%
-
Price per share
-
$16.27
-
Number of holders
-
142
-
Value change
-
-$3,509,843
-
Number of buys
-
63
-
Number of sells
-
63
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q1 2022
As of 31 Mar 2022,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,370,010 shares.
The largest 10 holders included
STATE STREET CORP, BlackRock Inc., VANGUARD GROUP INC, FMR LLC, EVENTIDE ASSET MANAGEMENT, LLC, Samsara BioCapital, LLC, MACQUARIE GROUP LTD, JACOBS LEVY EQUITY MANAGEMENT, INC, TWO SIGMA ADVISERS, LP, and MORGAN STANLEY.
This page lists
142
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.